Elena Nikulina

Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC

Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC
Bicara Therapeutics antibody breakthrough

Bicara Therapeutics Inc. has announced the development of Ficerafusp alfa, the first and only EGFR-directed antibody fused to a TGF-beta ligand trap, engineered for overcoming clinical challenges in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC).

The company will present three posters featuring long-term Phase 1b data, including contributions from leading academic partners such as UCLA, during the ASCO26 conference on Saturday, May 30. This advancement may open new paths in the treatment of patients with HPV-negative HNSCC, a segment with limited therapeutic options.

Bicara previously launched the FORTIFI clinical trial targeting first-line recurrent/metastatic HPV-negative HNSCC patients with poor prognosis. The company is also scheduled to present its first quarter 2026 financial results and business update in a public webcast on May 11. Both initiatives reflect Bicara’s ongoing focus on advancing treatment options for this patient population.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.